

Supplemental Figures for:

A Phase II Randomized Trial (G027827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer Johanna Bendell et al.

Figure S1. MET STEPPs for PFS. (A): 30 patients. (B): 40 patients.

Abbreviations: CI, confidence interval; HR, hazard ratio; MET, mesenchymal-epithelial transition; PFS, progression-free survival; STEPP, subpopulation treatment effect pattern plot.




Figure S2. HGF STEPPs. (A): PFS. (B): OS.

Abbreviations: CI, confidence interval; HGF, hepatocyte growth factor; OS, overall survival; PFS, progression-free survival; STEPP, subpopulation treatment effect pattern plot.




Figure S3. Exploratory subgroup analyses according to biomarker expression status. **(A):** PFS. **(B):** OS. Abbreviations: Bev, bevacizumab; CI, confidence interval; MET-Neg, mesenchymal-epithelial transition negative; MET-Pos, mesenchymal-epithelial transition positive; NE, not estimable; Ona, onartuzumab; OS, overall survival; Pbo, placebo; PFS, progression-free survival.

Α

Baseline Risk Factors	Total n	Pbo+Bev+FOLFOX (N = 74)			_	(N =	FOLFOX 73)			
		n	Events	Median (months)	n	Events	Median (months)	Hazard Ratio	95% Wald Cl	Ona+Bev+FOLFOX Pbo+Bev+FOLFOX Better Better
All patients	147	74	51	10.7	73	39	11.1	0.71	(0.46 to 1.09)	► ₩₩
KRAS status										
Mutant	79	38	26	12.1	41	21	11.0	0.86	(0.47 to 1.55)	₽—∔ ₩ ∔—4
Wild type	68	36	25	9.6	32	18	11.9	0.62	(0.33 to 1.14)	
KRAS + MET status										
Mutant + MET-Neg	46	20	16	11.5	26	13	12.6	0.55	(0.25 to 1.20)	⊢ ≣_∔∔ ∎
Mutant + MET-Pos	33	18	10	12.6	15	8	9.9	1.42	(0.53 to 3.76)	
Wild type + MET-Neg	40	20	15	10.3	20	11	16.3	0.50	(0.23 to 1.09)	
Wild type + MET-Pos	28	16	10	7.6	12	7	10.2	1.07	(0.40 to 2.83)	
BRAF										
Mutant	15	7	5	10.6	8	4	10.2	0.63	(0.16 to 2.39)	
Wild type	132	67	46	10.7	65	35	11.9	0.75	(0.48 to 1.18)	└── ───↓
PIK3CA										
Mutant	19	8	5	12.6	11	8	13.0	0.91	(0.28 to 2.98)	
Wild type	128	66	46	10.6	62	31	11.1	0.70	(0.44 to 1.11)	⊢ − _+

В

Baseline Risk Factors	Total n	F	Pbo+Bev+FOLFOX (N = 74)			Ona+Bev- (N =	FOLFOX 73)				
		n	Events	Median (months)	n	Events	Median (months)	Hazard Ratio	95% Wald Cl	Ona+Bev+FOLFOX Pbo+Bev+FOLFOX Better Better	
All patients	147	74	27	NE	73	28	26.3	1.02	(0.60 to 1.75)	► 1	
KRAS status											
Mutant	79	38	14	NE	41	15	26.3	1.02	(0.49 to 2.15)		
Wild type	68	36	13	19.2	32	13	NE	1.00	(0.46 to 2.18)		
KRAS + MET status											
Mutant + MET-Neg	46	20	8	NE	26	7	NE	0.66	(0.24 to 1.81)		
Mutant + MET-Pos	33	18	6	NE	15	8	14.2	1.73	(0.58 to 5.16)		
Wild type + MET-Neg	40	20	7	NE	20	7	NE	0.90	(0.31 to 2.58)		
Wild type + MET-Pos	28	16	6	18.8	12	6	19.2	1.23	(0.39 to 3.90)		
										1/8 1/3 1 3	